MBIO Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 4424.89%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Mustang Bio has higher upside potential than Armata Pharmaceuticals, analysts believe Mustang Bio is more attractive than Armata Pharmaceuticals.

Mustang Bio has a beta of 2.165, which suggesting that the stock is 116.485% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Mustang Bio's net income of -$153K is higher than Armata Pharmaceuticals's net income of -$6.5M. Notably, Mustang Bio's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 1,016.56x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cardiff Oncology has a net margin of -- compared to Mustang Bio's net margin of -12324.77%. Mustang Bio's return on equity of -- beat Cardiff Oncology's return on equity of -77.18%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 4424.89%. On the other hand Cardiff Oncology has an analysts' consensus of $12.07 which suggests that it could grow by 171.27%. Given that Mustang Bio has higher upside potential than Cardiff Oncology, analysts believe Mustang Bio is more attractive than Cardiff Oncology.

Mustang Bio has a beta of 2.165, which suggesting that the stock is 116.485% more volatile than S&P 500. In comparison Cardiff Oncology has a beta of 1.516, suggesting its more volatile than the S&P 500 by 51.624%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cardiff Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Cardiff Oncology pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Cardiff Oncology quarterly revenues of $109K. Mustang Bio's net income of -$153K is higher than Cardiff Oncology's net income of -$13.4M. Notably, Mustang Bio's price-to-earnings ratio is -- while Cardiff Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 401.92x for Cardiff Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Curis has a net margin of -- compared to Mustang Bio's net margin of -446.05%. Mustang Bio's return on equity of -- beat Curis's return on equity of -461.34%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 4424.89%. On the other hand Curis has an analysts' consensus of $16.33 which suggests that it could grow by 787.68%. Given that Mustang Bio has higher upside potential than Curis, analysts believe Mustang Bio is more attractive than Curis.

Mustang Bio has a beta of 2.165, which suggesting that the stock is 116.485% more volatile than S&P 500. In comparison Curis has a beta of 3.605, suggesting its more volatile than the S&P 500 by 260.513%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Curis pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Curis quarterly revenues of $2.4M. Mustang Bio's net income of -$153K is higher than Curis's net income of -$10.6M. Notably, Mustang Bio's price-to-earnings ratio is -- while Curis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 1.15x for Curis. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Mustang Bio's net margin of -35.79%. Mustang Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 4424.89%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Mustang Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Mustang Bio is more attractive than Protalix BioTherapeutics.

Mustang Bio has a beta of 2.165, which suggesting that the stock is 116.485% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Mustang Bio's net income of -$153K is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, Mustang Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.